Date: 2014-11-18
Type of information: Licensing agreement
Compound: adalimumab (Humira® biosimilar)
Company: Stada (Germany) mAbxience (Switzerland)
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases
Type agreement: licensing
Action mechanism:
Disease:
Details: * On November 18, 2014, Stada Arzneimittel AG and the biotech specialist mAbxience have agreed to negotiate over the in-licensing of an adalimumab (Humira®) biosimilar. The letter of intent stipulates that the two negotiating parties will come to a decision within the next six months. The original product, Humira® is the world\'s top-selling biopharmaceutical with a sales volume in 2013 of approximately $10.66 billion in 2013. With these negotiations, Stada continues its strategy of targeted in-licensing of selected biosimilars; a strategy with which the Group is continuously expanding its portfolio of quality products at comparably favorable conditions. It is planned to develop and manufacture the biosimilar adalimumab at the Genhelix biopharmaceutical plant located in Leon, Spain.
.
Financial terms:
Latest news:
